323 related articles for article (PubMed ID: 24259591)
1. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
[TBL] [Abstract][Full Text] [Related]
2. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
[TBL] [Abstract][Full Text] [Related]
3. Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability.
Cobo-Calvo A; Ruiz A; Richard C; Blondel S; Cavagna S; Strazielle N; Ghersi-Egea JF; Giraudon P; Marignier R
PLoS One; 2020; 15(9):e0238301. PubMed ID: 32881954
[TBL] [Abstract][Full Text] [Related]
4. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica.
Shimizu F; Nishihara H; Sano Y; Takeshita Y; Takahashi S; Maeda T; Takahashi T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0122000. PubMed ID: 25811465
[TBL] [Abstract][Full Text] [Related]
5. Sera from neuromyelitis optica patients disrupt the blood-brain barrier.
Shimizu F; Sano Y; Takahashi T; Haruki H; Saito K; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):288-97. PubMed ID: 22100760
[TBL] [Abstract][Full Text] [Related]
6. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
Uchida T; Mori M; Uzawa A; Masuda H; Muto M; Ohtani R; Kuwabara S
Mult Scler; 2017 Jul; 23(8):1072-1084. PubMed ID: 27682231
[TBL] [Abstract][Full Text] [Related]
7. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
[TBL] [Abstract][Full Text] [Related]
9. Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients.
Jasiak-Zatońska M; Michalak S; Osztynowicz K; Kozubski W; Kalinowska-Łyszczarz A
Neurol Neurochir Pol; 2022; 56(4):308-317. PubMed ID: 35029294
[TBL] [Abstract][Full Text] [Related]
10. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment.
Vincent T; Saikali P; Cayrol R; Roth AD; Bar-Or A; Prat A; Antel JP
J Immunol; 2008 Oct; 181(8):5730-7. PubMed ID: 18832732
[TBL] [Abstract][Full Text] [Related]
11. Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes: an in vitro study.
Saito K; Shimizu F; Koga M; Sano Y; Tasaki A; Abe M; Haruki H; Maeda T; Suzuki S; Kusunoki S; Mizusawa H; Kanda T
J Neurol Neurosurg Psychiatry; 2013 Jul; 84(7):756-65. PubMed ID: 23584494
[TBL] [Abstract][Full Text] [Related]
12. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.
Shimizu F; Schaller KL; Owens GP; Cotleur AC; Kellner D; Takeshita Y; Obermeier B; Kryzer TJ; Sano Y; Kanda T; Lennon VA; Ransohoff RM; Bennett JL
Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679661
[TBL] [Abstract][Full Text] [Related]
13. Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane.
Melamud L; Fernández JM; Rivarola V; Di Giusto G; Ford P; Villa A; Capurro C
J Neurosci Res; 2012 Jun; 90(6):1240-8. PubMed ID: 22354518
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
15. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
[TBL] [Abstract][Full Text] [Related]
16. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
17. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
18. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica.
Shimizu F; Takeshita Y; Hamamoto Y; Nishihara H; Sano Y; Honda M; Sato R; Maeda T; Takahashi T; Fujikawa S; Kanda T
Ann Clin Transl Neurol; 2019 Oct; 6(10):2079-2087. PubMed ID: 31568704
[TBL] [Abstract][Full Text] [Related]
19. NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement.
Haruki H; Sano Y; Shimizu F; Omoto M; Tasaki A; Oishi M; Koga M; Saito K; Takahashi T; Nakada T; Kanda T
J Neurol Sci; 2013 Aug; 331(1-2):136-44. PubMed ID: 23809190
[TBL] [Abstract][Full Text] [Related]
20. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
